Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218496 | 1.00 | CTSK (0.45) | CTSKCTSSATMMAPTPPARA | |
| SCHEMBL8529886 | 1.00 | CTSK (0.45) | CTSKCTSSATMMAPTPPARA | |
| SCHEMBL9293004 | 1.00 | CTSK (0.45) | CTSKCTSSATMMAPTPPARA | |
| SCHEMBL10463737 | 0.91 | CTSK (0.43) | CTSKCTSSATMMAPT | |
| SCHEMBL8911849 | 0.91 | CTSK (0.43) | CTSKCTSSATMMAPTPPARA | |
| SCHEMBL8911855 | 0.88 | CTSK (0.41) | CTSKCTSSATMMAPTPPARA | |
| SCHEMBL7065105 | 0.87 | CTSK (0.41) | CTSKCTSSATMPPARAPPARG | |
| SCHEMBL9292986 | 0.83 | MAPT (0.45) | CTSKCTSSATMMAPTAKT1 | |
| SCHEMBL9293035 | 0.82 | ALDH1A1 (0.51) | — | |
| SCHEMBL8314307 | 0.82 | ALDH1A1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847111-B2 | Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III | CANADA INC. (CA) | 2010-12-07 | — | — | US | claimed |
| EP-2688877-B1 | SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20150073159-A1 | Solid State Forms Of Cabazitaxel And Processes For Preparation Thereof | PLUS CHEMICALS SA (CH) | 2015-03-12 | — | — | US | disclosed |
| US-8921411-B2 | Solid state forms of cabazitaxel and processes for preparation thereof | PLUS CHEMICALS SA (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20140011865-A1 | SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF | PLUS CHEMICALS SA (CH) | 2014-01-09 | — | — | US | disclosed |
| US-7847111-B2 | Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III | CANADA INC. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20070293687-A1 | SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III | 6570763 CANADA INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-6596880-B1 | Esterification of baccatine derivative | AVENTIS PHARMA S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-5977375-A | Esters of baccatin III and 10-deacetylbaccatin III | RHONE-POULENC RORER S.A. (FR) | 1999-11-02 | — | — | US | disclosed |
| US-5717103-A | Process for the esterification of baccatin III and of 10-deacetylbaccatin III | RHONE-POULENC RORER S.A. (FR) | 1998-02-10 | — | — | US | disclosed |
| US-5606068-A | Acid anhydrides, their preparation and their use | RHONE-POULENC RORER S.A. (FR) | 1997-02-25 | — | — | US | disclosed |
| US-5578739-A | Process for the preparation of Baccatin III and 10-deacetylbaccatin III derivatives | RHONE-POULENC RORER S.A. (FR) | 1996-11-26 | — | — | US | disclosed |
| US-5463106-A | Process for the enantioselective preparation of phenylisosrine derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1995-10-31 | — | — | US | disclosed |
| US-5304670-A | Process for the enantioselective preparation of phenylisoserine derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293687-A1 | SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KAT5, KYAT3 | CTSK 1320/4885CTSS 2680/4885ATM 882/4885 |
| US-20150073159-A1 | Solid State Forms Of Cabazitaxel And Processes For Preparation Thereof | KLK3, AR, KLK4 | CTSK 739/4885CTSS 1486/4885ATM 1331/4885 |
| US-20140011865-A1 | SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF | KLK3, AR, KLK4 | CTSK 769/4885CTSS 1474/4885ATM 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.